8th Annual Heart in Diabetes (HiD) CME Conference

8th Annual Heart in Diabetes (HiD) CME Conference is organized by The Metabolic Institute of America (TMIOA) and will be held from Jun 07 - 09, 2024 at Hilton Philadelphia at Penn's Landing, Philadelphia, Pennsylvania, United States of America.

Learning Objectives:
Upon completion of this meeting, participants should be able to:
• Evaluate the extent of vascular disease in diabetes, obesity, and cardiometabolic syndrome.
• Be able to assess cardiovascular risk in diabetes.
• Describe the different etiologies of cardiomyopathies.
• Provide comprehensive management of diabetes, addressing obesity, hypertension, dyslipidemia as well as hyperglycemia.
• Describe optimal use of technology—specifically CGM—and digital technology and their impact on diabetes and CVD
• Be able to recognize and manage hypoglycemia and its impact on comorbidities
• Evaluate stroke in diabetes and cardiorenal metabolic disease
• Be able to evaluate prevent and manage atherosclerosis and ASCVD
• Recognize the full spectrum of Heart Failure dictating approach to management
• Know GDMT in the 4 Pillar management of HFrEF
• Develop contemporary management of HFpEF
• Discuss the impact of obesity and diets on fatty liver, CKD, CVD, and HF
• Evaluate the evidence supporting the use of GLP1-RAs, SGLT inhibitors, nonsteroidal MRAs, and other treatments to reduce CKD, HF, and cardiovascular disease and mortality in patients with T2D
• Describe new and evolving agents in dyslipidemia treatment and how they can be used to reduce ASCVD
• Explain the important role of Lp(a) in the development atherosclerosis
• Understand the potential role and impact of AHA Presidential Advisory on Cardio-Kidney-Metabolic Health
• Discuss the changes in diagnosis and management based on DCRM 2.0 Global Multispecialty Practice Recommendations
• Evaluate the impact on clinical practice of new CVOTs, including those evaluating antihyperglycemic, lipid-lowering, and other medications such as nonsteroidal MRAs and anticoagulation therapies
• Understand the role of GLP1-RAs in prevention of CVD, strokes, and CKD in diabetes and obesity
• Describe the state of heart disease in women
• Discuss diabetes, CKD, CVD, and HF in diverse populations
• Develop treatment plans to prevent and manage CKD and its complications with ACE/ARB, SGLT inhibitors, finerenone, and GLP1-RAs in combination.